Drug Profile


Alternative Names: ND-0801; Opipramol/nicotine

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator NeuroDerm
  • Class Alkaloids; Behavioural disorder therapies; Pyridines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Histamine H1 receptor antagonists; Nicotinic receptor agonists; Opioid receptor agonists; Serotonin 2 receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Jan 2016 Phase I/II development is ongoing in Israel
  • 05 Nov 2012 NeuroDerm completes enrolment in its phase I/IIa trial for Attention-deficit hyperactivity disorder in Israel (NCT01174355)
  • 12 Oct 2010 Phase-I/II clinical trials in Attention-deficit hyperactivity disorder in Israel (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top